Hildegunn Hoberg-Vetti
Overview
Explore the profile of Hildegunn Hoberg-Vetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hendricks L, Verbeek K, Schuurs-Hoeijmakers J, Mensenkamp A, Brems H, de Putter R, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473316
Females with PTEN Hamartoma Tumor Syndrome (PHTS) have breast cancer risks up to 76%. This study assessed associations between breast cancer and lifestyle in European female adult PHTS patients. Data...
2.
Bassi N, Hovland H, Rasheed K, Jarhelle E, Pedersen N, Mchaina E, et al.
BMC Cancer
. 2023 Apr;
23(1):368.
PMID: 37085799
Background: Damaging alterations in the BRCA1 gene have been extensively described as one of the main causes of hereditary breast and ovarian cancer (HBOC). BRCA1 alterations can lead to impaired...
3.
Hovland H, Mchaina E, Hoberg-Vetti H, Ariansen S, Sjursen W, Van Ghelue M, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833189
The BRCA1 protein is implicated in numerous important cellular processes to prevent genomic instability and tumorigenesis, and pathogenic germline variants predispose carriers to hereditary breast and ovarian cancer (HBOC). Most...
4.
Hendricks L, Hoogerbrugge N, Mensenkamp A, Brunet J, Lleuger-Pujol R, Hoberg-Vetti H, et al.
J Natl Cancer Inst
. 2022 Sep;
115(1):93-103.
PMID: 36171661
Background: PTEN Hamartoma Tumor Syndrome (PHTS) is a rare syndrome with a broad phenotypic spectrum, including increased risks of breast (BC, 67%-78% at age 60 years), endometrial (EC, 19%-28%), and...
5.
Decker M, Agarwal A, Benneche A, Churpek J, Duployez N, Duvall A, et al.
Blood Adv
. 2022 Jan;
6(11):3195-3200.
PMID: 35026845
Familial platelet disorder with associated myeloid malignancies (RUNX1-familial platelet disorder [RUNX1-FPD]) is caused by heterozygous pathogenic germline variants of RUNX1. In the present study, we evaluate the applicability of transactivation...
6.
Hovland H, Al-Adhami R, Ariansen S, Van Ghelue M, Sjursen W, Lima S, et al.
Fam Cancer
. 2022 Jan;
21(4):389-398.
PMID: 34981296
Pathogenic germline variants in Breast cancer susceptibility gene 1 (BRCA1) predispose carriers to hereditary breast and ovarian cancer (HBOC). Through genetic testing of patients with suspected HBOC an increasing number...
7.
Hoberg-Vetti H, Ognedal E, Buisson A, Vamre T, Ariansen S, Hoover J, et al.
Eur J Hum Genet
. 2020 Mar;
28(8):1078-1086.
PMID: 32203205
Rare sequence variants in the non-coding part of the BRCA genes are often reported as variants of uncertain significance (VUS), which leave patients and doctors in a challenging position. The...
8.
Grolleman J, de Voer R, Elsayed F, Nielsen M, Weren R, Palles C, et al.
Cancer Cell
. 2019 Feb;
35(2):256-266.e5.
PMID: 30753826
Biallelic germline mutations affecting NTHL1 predispose carriers to adenomatous polyposis and colorectal cancer, but the complete phenotype is unknown. We describe 29 individuals carrying biallelic germline NTHL1 mutations from 17...
9.
Hoberg-Vetti H, Eide G, Siglen E, Listol W, Tveit Haavind M, Hoogerbrugge N, et al.
Acta Oncol
. 2018 Oct;
58(2):175-181.
PMID: 30334464
Background: Genetic testing is increasing in patients newly diagnosed with cancer. This study investigated the levels, course and predictors of cancer-related distress, defined as intrusion and avoidance, in women undergoing...
10.
Lonning P, Berge E, Bjornslett M, Minsaas L, Chrisanthar R, Hoberg-Vetti H, et al.
Ann Intern Med
. 2018 Jan;
168(5):326-334.
PMID: 29335712
Background: The role of normal tissue gene promoter methylation in cancer risk is poorly understood. Objective: To assess associations between normal tissue BRCA1 methylation and ovarian cancer risk. Design: 2...